# VRCA catalysts: Verrica Pharmaceuticals Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vrca/catalysts

> Verrica Pharmaceuticals Inc. (VRCA) has 8 upcoming catalysts. The next is the ruxotemitide topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for VRCA?

Verrica Pharmaceuticals Inc. (VRCA) has 8 upcoming catalysts. The next is the ruxotemitide topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "- Enrollment completed in the first of two pivotal trials in the global Phase 3 common warts program, with topline data for each trial expected in Q1 2027 and mid-2027, respectively -" [Calendar and source filings](https://sec-api.dev/companies/vrca/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-458527, https://www.sec.gov/Archives/edgar/data/1660334/000119312526458527/d144356dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/vrca/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Verrica Pharmaceuticals Inc. |
| Ticker | VRCA (Nasdaq) |
| SEC CIK | 1660334 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/vrca |

## Cash runway

Cash $14.4M as of 2026-09-30; quarterly burn $9.0M; about 4.8 months of runway at that rate (XBRL company facts, accession 0001660334-26-000030).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 13, 2020 | [YCANTH (cantharidin) complete response letter (CRL)](https://sec-api.dev/pdufa/cantharidin) | VRCA |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22212905_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| Feb 2021 | [YCANTH (cantharidin) NDA/BLA acceptance](https://sec-api.dev/pdufa/cantharidin) | VRCA |  | completed | "In February 2021, we received notice that the FDA accepted the resubmitted NDA for filing, with a PDUFA goal date of June 23, 2021." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1660334/000119312524263473/d817723d424b5.htm)) |
| September 16, 2021 | [YCANTH (cantharidin) complete response letter (CRL)](https://sec-api.dev/pdufa/cantharidin) | VRCA |  | completed, complete response letter | "We have completed our review of this application, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22212905_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| September 17, 2021 | [Verrica Pharmaceuticals Inc. complete response letter (CRL)](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed, complete response letter | "On September 17, 2021, the FDA issued a CRL regarding our NDA for" ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1660334/000119312524263473/d817723d424b5.htm)) |
| November 29, 2021 | [YCANTH (cantharidin) NDA/BLA submission](https://sec-api.dev/pdufa/cantharidin) | VRCA | molluscum | completed | "With the satisfactory resolution of the facility inspection, we resubmitted the NDA for the approval of VP-102 for the treatment of molluscum on November 29, 2021." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1660334/000119312524263473/d817723d424b5.htm)) |
| December 15, 2021 | [YCANTH (cantharidin) NDA/BLA acceptance](https://sec-api.dev/pdufa/cantharidin) | VRCA |  | completed | "On December 15, 2021 the FDA accepted our NDA resubmission for VP-102 and assigned a new PDUFA goal date of May 24, 2022." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1660334/000119312524263473/d817723d424b5.htm)) |
| Apr 2022 | [Ruxotemitide trial start](https://sec-api.dev/pdufa/ruxotemitide) | VRCA | biopsy proven BCC | completed | "In April 2022, we dosed the first patient in Part 1 of a three-part Phase 2, multicenter, open-label, dose-escalation proof-of-concept trial with a safety run-in designed to assess the safety, pharmacokinetics, and efficacy in subjects with biopsy proven BCC." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1660334/000095017025037172/vrca-20241231.htm)) |
| May 23, 2022 | [YCANTH (cantharidin) complete response letter (CRL)](https://sec-api.dev/pdufa/cantharidin) | VRCA |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22212905_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| July 21, 2023 | [YCANTH (cantharidin) FDA approval](https://sec-api.dev/pdufa/cantharidin) | VRCA | molluscum contagiosum and began capitalizing inventory purchases of saleable product | completed, approved | "On July 21, 2023, the Company received FDA approval for YCANTH (VP-102) for the treatment of molluscum and began capitalizing inventory purchases of saleable product from certain suppliers." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1660334/000166033426000008/vrca-20251231.htm)) |
| Oct 2024 | [Verrica Pharmaceuticals Inc. interim data readout](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed, positive | "In October 2024, the Company presented two posters at the 2024 Fall Clinical Dermatology Conference featuring positive preliminary topline results from Part 2 of the Phase 2 study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312525051957/d937567dex991.htm)) |
| March 11, 2025 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312525051957/d937567dex991.htm)) |
| May 13, 2025 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312525118839/d88474dex991.htm)) |
| August 8, 2025 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312525178954/d409147dex991.htm)) |
| November 14, 2025 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312525283078/d99039dex991.htm)) |
| January 7, 2026 | [YCANTH (cantharidin) trial start](https://sec-api.dev/pdufa/cantharidin) | VRCA | common warts in December 2025, and Company expects to initiate the second Phase 3 study | completed | "On January 7, 2026, the Company announced that the first patient was dosed in December 2025 in the first trial (COVE-2) of our global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529dex991.htm)) |
| March 11, 2026 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/d94203dex991.htm)) |
| May 12, 2026 | [YCANTH (cantharidin) trial start](https://sec-api.dev/pdufa/cantharidin) | VRCA | common warts | completed | "Further, last December the first patient was dosed in the first trial (COVE-2) of the global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts, and we are happy to announce achievement of over 50% of the current targeted enrollment in the trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529dex991.htm)) |
| May 12, 2026 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529dex991.htm)) |
| August 6, 2026 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828dex991.htm)) |
| November 2026 | [VP-102 primary completion](https://sec-api.dev/pdufa/vp-102) | VRCA | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV) | scheduled | "NCT07246590 (Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Verrica Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07246590)) |
| Nov 2026 to Feb 2027 | [VP-102 topline data readout](https://sec-api.dev/pdufa/vp-102) | VRCA | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV) | scheduled | "NCT07246590 (Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Verrica Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07246590)) |
| November 12, 2026 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526458527/d144356dex991.htm)) |
| Q1 2027 | [Ruxotemitide topline data readout](https://sec-api.dev/pdufa/ruxotemitide) | VRCA |  | scheduled | "- Enrollment completed in the first of two pivotal trials in the global Phase 3 common warts program, with topline data for each trial expected in Q1 2027 and mid-2027, respectively -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526458527/d144356dex991.htm)) |
| mid-2027 | [YCANTH (cantharidin) topline data readout](https://sec-api.dev/pdufa/cantharidin) | VRCA |  | scheduled | "Based upon current projections, the Company expects to present topline data from the program in mid-2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828dex991.htm)) |
| April 2027 | [VP-102 primary completion](https://sec-api.dev/pdufa/vp-102) | VRCA | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV) | scheduled | "NCT07881952 (Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Verrica Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07881952)) |
| Apr to Jul 2027 | [VP-102 topline data readout](https://sec-api.dev/pdufa/vp-102) | VRCA | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV) | scheduled | "NCT07881952 (Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Verrica Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07881952)) |
| May 2027 | [Vp-102 (us) / to-208 (japan) primary completion](https://sec-api.dev/pdufa/vp-102-us-to-208-japan) | VRCA | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV) | scheduled | "NCT07637734 (Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Verrica Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07637734)) |
| May to Aug 2027 | [Vp-102 (us) / to-208 (japan) topline data readout](https://sec-api.dev/pdufa/vp-102-us-to-208-japan) | VRCA | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV) | scheduled | "NCT07637734 (Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Verrica Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07637734)) |
| November 2027 | [YCANTH (cantharidin) primary completion](https://sec-api.dev/pdufa/cantharidin) | VRCA | Common Warts (Verruca Vulgaris); Common Warts; Human Papilloma Virus (HPV) | scheduled | "NCT07457918 (Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Verrica Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07457918)) |
| Nov 2027 to Feb 2028 | [YCANTH (cantharidin) topline data readout](https://sec-api.dev/pdufa/cantharidin) | VRCA | Common Warts (Verruca Vulgaris); Common Warts; Human Papilloma Virus (HPV) | scheduled | "NCT07457918 (Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Verrica Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07457918)) |

## Drugs

- [YCANTH (cantharidin)](https://sec-api.dev/pdufa/cantharidin): common warts, molluscum contagiosum and began capitalizing inventory purchases of saleable product, molluscum, molluscum and began capitalizing inventory purchases of saleable product, common warts in december 2025, and company expects to initiate the second phase 3 study, molluscum contagiosum in adult and pediatric patients two years of age and older, Common Warts (Verruca Vulgaris)
- [Ruxotemitide](https://sec-api.dev/pdufa/ruxotemitide): biopsy proven bcc
- [VP-102](https://sec-api.dev/pdufa/vp-102): Common Warts
- [Vp-102 (us) / to-208 (japan)](https://sec-api.dev/pdufa/vp-102-us-to-208-japan): Common Warts

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vrca/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VRCA catalysts: Verrica Pharmaceuticals Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vrca/catalysts

```bibtex
@misc{secapidev_companies_vrca_catalysts_20261116,
  title        = {VRCA catalysts: Verrica Pharmaceuticals Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vrca/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vrca_catalysts_20261116","title":"VRCA catalysts: Verrica Pharmaceuticals Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vrca/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
